BRIEF published on 12/11/2025 at 23:05, 7 days 15 hours ago Xenetic Biosciences ajourne son assemblée générale annuelle des actionnaires de 2025. Instructions De Vote Quorum Biosciences Xénétiques Assemblée Générale Des Actionnaires Ajournement De 2025
BRIEF published on 12/11/2025 at 23:05, 7 days 15 hours ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 7 days 15 hours ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 29 days 23 hours ago Xenetic Biosciences étend sa collaboration avec Scripps Research Biopharmaceutique Traitement Du Cancer DNase I Thérapie CAR-T Recherche Scripps
BRIEF published on 11/19/2025 at 14:50, 29 days 23 hours ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 1 month ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 1 month 5 days ago Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2025 Résultats Financiers Essais Cliniques Augmentation Des Revenus Technologie DNase Carcinome Pancréatique
BRIEF published on 11/13/2025 at 14:50, 1 month 5 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 1 month 6 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 2 months 8 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
Published on 12/19/2025 at 14:40, 5 minutes ago Northern Superior Announces Closing of the Arrangement
Published on 12/19/2025 at 13:30, 1 hour 15 minutes ago Quartz Commences Trading On The OTCQX Best Market Under The Symbol QZMRF
Published on 12/19/2025 at 13:30, 1 hour 15 minutes ago DataMetrex Announces Closing of Yuzu Payment Processing Solution Acquisition
Published on 12/19/2025 at 13:30, 1 hour 15 minutes ago Sterling Metals Provides Year End Update to Stakeholders
Published on 12/19/2025 at 13:05, 1 hour 40 minutes ago Roxmore Resources Begins Trading on the OTCQX Best Market in the United States
Published on 12/19/2025 at 14:05, 40 minutes ago ETHGas Debuts Ethereum's Blockspace Futures Market with $800m of Commitments and $12m Seed Round Led by Polychain Capital
Published on 12/19/2025 at 14:00, 45 minutes ago EQS-Adhoc: EVAN Group plc: Delisting of Bond has been resolved
Published on 12/19/2025 at 13:31, 1 hour 14 minutes ago North Peak Confirms Historic Waste Rock Pile Mineralisation with Sonic Drilling and Completion of 2025 Reverse Circulation Exploration Drilling Program at Prospect Mountain, Nevada
Published on 12/19/2025 at 13:18, 1 hour 27 minutes ago Gennaker offshore wind farm obtains construction and operations permit
Published on 12/19/2025 at 13:15, 1 hour 30 minutes ago PATRIMOINE ET COMMERCE: Descriptif du programme de rachat d’actions autorisé par l’assemblée générale mixte des actionnaires du 12 juin 2025 et lancement d’un programme de rachat d’actions
Published on 12/19/2025 at 08:30, 6 hours 15 minutes ago Share capital decrease by way of treasury shares cancellation
Published on 12/19/2025 at 08:30, 6 hours 15 minutes ago Réduction du capital par voie d’annulation d’actions propres
Published on 12/19/2025 at 07:00, 7 hours 45 minutes ago EURAZEO ANNONCE AVOIR MENÉ AVEC SUCCÈS UNE TRANSACTION ACCÉLÉRANT SA ROTATION D'ACTIFS
Published on 12/19/2025 at 07:00, 7 hours 45 minutes ago EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION
Published on 12/18/2025 at 18:30, 20 hours 15 minutes ago Schneider Electric completes transaction to acquire remaining 35% stake in existing Indian JV
